Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventric...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Yu F Osmolovskaya, I V Zhirov, S N Tereshchenko
Formato:	Artigo
Idioma:	Russian
Publicado em:	"Consilium Medicum" Publishing house 2015-09-01
Colecção:	Терапевтический архив
Assuntos:	aldosterone mineralocorticoid receptor antagonists chronic heart failure
Acesso em linha:	https://ter-arkhiv.ru/0040-3660/article/view/31823

Registos relacionados

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
Por: S N Tereshchenko, et al.
Publicado em: (2013-12-01)

Heart failure: the role for mineralocorticoid receptor antagonists
Por: Bertram Pitt
Publicado em: (2014-05-01)

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review
Por: Natalia V. Safronova, et al.
Publicado em: (2022-01-01)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
Por: Jason M. Duran, et al.
Publicado em: (2020-04-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
Por: A. M. Esayan, et al.
Publicado em: (2018-04-01)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
Por: Josefin Henrysson, et al.
Publicado em: (2023-02-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Por: Daiji Kawanami, et al.
Publicado em: (2021-10-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
Por: MG Bubnova
Publicado em: (2014-12-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Por: Yuta Tezuka, et al.
Publicado em: (2021-03-01)

Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis.
Por: Mary Elizabeth Moss, et al.
Publicado em: (2015-09-01)

Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients
Por: Pascal R. D. Clephas, et al.
Publicado em: (2023-04-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
Por: Takuro Abe, et al.
Publicado em: (2020-10-01)

Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis
Por: Arga Setyo Adji, et al.
Publicado em: (2024-11-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
Por: Irina N. Bobkova
Publicado em: (2023-11-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
Por: Shuhui Zhai, et al.
Publicado em: (2024-09-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
Por: Memory MUKANGWA, et al.
Publicado em: (2019-12-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
Por: O. A. Osipova, et al.
Publicado em: (2021-11-01)

Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure
Por: Ida Löfman, et al.
Publicado em: (2018-07-01)

The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.
Por: Eqerem Hasani, et al.
Publicado em: (2022-01-01)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
Por: Sho Suzuki, et al.
Publicado em: (2020-10-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
Por: N. A. Nuritdinov, et al.
Publicado em: (2020-12-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
Por: Houry Puzantian, et al.
Publicado em: (2024-12-01)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
Por: Chang Geng, et al.
Publicado em: (2023-11-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
Por: Kisho Miyasako, et al.
Publicado em: (2024-12-01)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
Por: Luo Shi, et al.
Publicado em: (2019-11-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Por: Ulrich Kintscher, et al.
Publicado em: (2023-06-01)

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
Por: Nappi J, et al.
Publicado em: (2011-06-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
Por: Chien‐Wei Huang, et al.
Publicado em: (2025-02-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
Por: A. G. Evdokimova, et al.
Publicado em: (2023-01-01)

Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease
Por: Andrei Niculae, et al.
Publicado em: (2022-03-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Por: Nina Vodošek Hojs, et al.
Publicado em: (2021-06-01)

Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans
Por: Irene Lucía Ennis, et al.
Publicado em: (2021-01-01)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
Por: Greg H. Tesch, et al.
Publicado em: (2017-05-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
Por: S. R. Gilyarevsky, et al.
Publicado em: (2023-10-01)

Heart failure as a complication of myocardial infarction: rational therapy. Case report
Por: Igor V. Zhirov, et al.
Publicado em: (2022-12-01)

New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
Por: Natalia A. Dragomiretskaya, et al.
Publicado em: (2021-09-01)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Por: Dong-Lim Kim, et al.
Publicado em: (2023-02-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
Por: Stephen eOrena, et al.
Publicado em: (2013-10-01)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
Por: Marie Pieronne‐Deperrois, et al.
Publicado em: (2021-06-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
Por: Sofia S. Pereira, et al.
Publicado em: (2021-04-01)